Aiforia® Breast Cancer Suite
AI-powered histological grading and IHC marker assessment for breast cancer diagnostics
Company profile
Company profile
Aiforia Technologies is a digital pathology company that transforms pathology image analysis through artificial intelligence, enabling better care for each patient. The company equips pathologists and scientists in clinical, pre-clinical, and academic laboratories with powerful deep learning AI and cloud-based technology designed to increase the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology. Aiforia's comprehensive portfolio includes CE-IVD marked Clinical Suites for breast, lung, prostate, gastric, and colorectal cancers, offering fully automated case-centric workflows that enhance diagnostic accuracy and productivity. These solutions provide AI-driven image analysis, standardized scoring, and automated reporting to achieve objective, quantitative, and explainable results. The company's research solutions offer study-centric workflows and pathology image analysis applications that cater to all research areas, empowering pathologists and scientists to make discoveries while automating repetitive tasks within GLP frameworks. At the core of Aiforia's offering is Aiforia® Create, a versatile cloud-based tool for developing deep learning AI models for image analysis in digital pathology. Its collaborative working environment allows multiple users to work together in real time from anywhere in the world, with an intuitive user interface that enables fast adoption even without prior AI experience. Aiforia's solutions integrate with existing laboratory infrastructure and are deployed in clinical settings worldwide, serving pathology laboratories, research institutions, pharmaceutical companies, and veterinary diagnostic labs.
Company description Aiforia official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas deployment with recorded integration context.
Company milestones
Announced next generation CE-IVD marked Prostate Cancer Biopsy AI solution. Expanded clinical suite portfolio across multiple cancer types.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
AI-powered histological grading and IHC marker assessment for breast cancer diagnostics
AI solutions for colorectal cancer diagnostics and recurrence prediction
AI-powered recurrence prediction for colorectal cancer treatment decisions
Cloud-based AI development tool for building deep learning models in digital pathology
AI detection of gastric cancer and Helicobacter pylori in whole slide images
AI-driven PD-L1 scoring for lung cancer to reduce errors and standardize assessments
AI detection and quantification of colorectal cancer metastases in lymph nodes
Next-generation AI solution for comprehensive prostate needle biopsy analysis and reporting
Fully automated study-centric workflows for pathology image analysis in research
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Veterinary pathology · Aug 31, 2026
Histological AI-Assisted Analysis Outperforms Pathologist Assessment in Predicting Disease Outcomes in PSC Patients.Hepatology research : the official journal of the Japan Society of Hepatology · Jul 29, 2026
High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma.Cancer treatment and research communications · Jul 29, 2026
Utility of quantitative pathologic analysis of pT1 colorectal carcinomas to improve prediction of lymph node metastasis.Virchows Archiv : an international journal of pathology · Jun 1, 2026
From Tissue Architecture To Genetic Signature: Artificial intelligence-based Analysis of Reticulin Framework and Clinical Variables Predicts Molecular Cluster in Paragangliomas.Endocrine pathology · Feb 18, 2026
MesoRet: a reticulin stain-based deep learning algorithm to assist diffuse mesothelioma subtyping.Pathologica · Feb 1, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Analyzing large and complex medical images in pathology
Comprehensive analysis and reporting of biopsies
AI-driven image analysis and standardized scoring
Development and validation of Colorectal Cancer QuantCRC for recurrence prediction
Development of Lymph Node Metastasis AI model for colorectal cancer detection
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Aiforia's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.